PE78899A1 - Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona - Google Patents

Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona

Info

Publication number
PE78899A1
PE78899A1 PE1998000466A PE00046698A PE78899A1 PE 78899 A1 PE78899 A1 PE 78899A1 PE 1998000466 A PE1998000466 A PE 1998000466A PE 00046698 A PE00046698 A PE 00046698A PE 78899 A1 PE78899 A1 PE 78899A1
Authority
PE
Peru
Prior art keywords
piridil
etoxi
bencil
diona
thiazolidin
Prior art date
Application number
PE1998000466A
Other languages
English (en)
Spanish (es)
Inventor
Hamish Ross
Robin Price
Jeffrey Roger Granett
Jaikrishna Patel
Paul Nigel Wray
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of PE78899A1 publication Critical patent/PE78899A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
PE1998000466A 1997-06-05 1998-06-05 Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona PE78899A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition

Publications (1)

Publication Number Publication Date
PE78899A1 true PE78899A1 (es) 1999-10-22

Family

ID=26311662

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000466A PE78899A1 (es) 1997-06-05 1998-06-05 Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona

Country Status (29)

Country Link
EP (1) EP0998284A1 (pt)
JP (1) JP2001521553A (pt)
KR (1) KR20010013410A (pt)
CN (3) CN1526391A (pt)
AP (1) AP1214A (pt)
AR (2) AR008198A1 (pt)
AU (1) AU8215098A (pt)
BG (1) BG104048A (pt)
BR (1) BR9810405A (pt)
CA (2) CA2333352A1 (pt)
CO (1) CO4940400A1 (pt)
DZ (1) DZ2510A1 (pt)
EA (1) EA002384B1 (pt)
GB (1) GB9711683D0 (pt)
HU (1) HUP0004070A3 (pt)
ID (1) ID24264A (pt)
IL (1) IL133074A0 (pt)
MX (1) MXPA99011322A (pt)
NO (2) NO995938L (pt)
NZ (2) NZ523725A (pt)
OA (1) OA11306A (pt)
PE (1) PE78899A1 (pt)
PL (1) PL337201A1 (pt)
SK (1) SK164899A3 (pt)
TR (2) TR200002790T2 (pt)
TW (1) TW570797B (pt)
UY (1) UY25032A1 (pt)
WO (1) WO1998055122A1 (pt)
ZA (2) ZA984826B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1598A (en) * 1999-04-23 2006-04-26 Smithkline Beecham Plc Polymorph of 5-[4-[2-(N-methyl-N-(2-pyridyl) amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt.
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
EP1173434B1 (en) 1999-04-23 2003-08-20 SmithKline Beecham plc Thiazolidinedione derivative and its use as antidiabetic
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
EP2270007A1 (en) * 2006-05-09 2011-01-05 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306228B1 (en) * 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
WO1995021608A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
SK16498A3 (en) * 1995-08-10 1999-03-12 Warner Lambert Co A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997018811A1 (en) * 1995-11-17 1997-05-29 Warner-Lambert Company A method of treating myotonic dystrophy
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
BR9710272A (pt) * 1996-07-12 1999-08-10 Smithkline Beecham Plc Novo tratamento de resisténcia a leptina

Also Published As

Publication number Publication date
CN1526391A (zh) 2004-09-08
NO995938L (no) 2000-02-02
CA2292629A1 (en) 1998-12-10
TR199902963T2 (xx) 2000-02-21
AR008198A1 (es) 1999-12-29
OA11306A (en) 2003-10-22
UY25032A1 (es) 1998-11-26
PL337201A1 (en) 2000-08-14
BG104048A (bg) 2000-07-31
BR9810405A (pt) 2000-08-29
GB9711683D0 (en) 1997-08-06
DZ2510A1 (fr) 2003-01-25
CO4940400A1 (es) 2000-07-24
ID24264A (id) 2000-07-13
CA2292629C (en) 2004-01-06
TW570797B (en) 2004-01-11
EA002384B1 (ru) 2002-04-25
WO1998055122A1 (en) 1998-12-10
ZA9811572B (en) 1999-07-22
IL133074A0 (en) 2001-03-19
HUP0004070A2 (hu) 2002-02-28
CN1112926C (zh) 2003-07-02
TR200002790T2 (tr) 2001-11-21
KR20010013410A (ko) 2001-02-26
MXPA99011322A (es) 2004-12-02
NZ523725A (en) 2004-09-24
SK164899A3 (en) 2000-11-07
AU8215098A (en) 1998-12-21
AR015120A1 (es) 2001-04-18
NO995938D0 (no) 1999-12-03
NZ513922A (en) 2001-09-28
NO20040738L (no) 2000-02-02
EP0998284A1 (en) 2000-05-10
CN1259050A (zh) 2000-07-05
AP1214A (en) 2003-10-08
ZA984826B (en) 1999-08-03
EA199901116A1 (ru) 2000-06-26
AP9901696A0 (en) 1999-12-31
CN1430959A (zh) 2003-07-23
CA2333352A1 (en) 1998-12-10
JP2001521553A (ja) 2001-11-06
HUP0004070A3 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
PE78899A1 (es) Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
TR200001880T2 (tr) İtrakonazolün bir oral preparasyonunun bileşiği ve yöntemi.
PE20000550A1 (es) Composicion de un derivado de bencimidazol util como anti-viral y anti-hiv
AR019636A1 (es) Dispositivo para el acoplamiento de dientes de excavadoras.
MA30598B1 (fr) Composition pharmaceutique contenant un acide tetrahydrofolique.
AR057970A2 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones
ES2165833T1 (es) Composicion farmaceutica revestida enterica y procedimiento de fabricacion.
EP1106210A3 (en) Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
JO2239B1 (en) Method for preparing benzothophen derivatives
ATE212991T1 (de) Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
PE20061373A1 (es) Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
BR0114196A (pt) Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas.
BR0111868A (pt) Composições farmacêuticas
PT833640E (pt) Composicao farmaceutica contendo lamotrigina
EA200702648A1 (ru) Фармацевтическая композиция, пригодная для введения один раз в день
ES2180573T3 (es) Uso de derivados de indol como antagonistas de 5ht1.
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
ID27649A (id) Proses pembuatan kertas
ATE254122T1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
PE61699A1 (es) Composicion farmaceutica de lamivudina
EP1064949A3 (en) Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications
UY25051A1 (es) Composiciones para el tratamiento de diabetes mellitus
EA200300234A1 (ru) Тартратные соли производного тиазолидиндиона

Legal Events

Date Code Title Description
FC Refusal